In a post hoc analysis of the PARAGON-HF trial, Scott D. Solomon, MD, of the Division of Cardiovascular Medicine at Brigham and Women’s Hospital, and colleagues evaluated how atrial fibrillation and atrial flutter affected the results.

The REDUCE-IT trial found patients at risk had reduced important ischemic events with icosapent ethyl. Prakriti Gaba, MD, and Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital, and colleagues, conducted a post hoc analysis limited to patients in the trial who had a history of myocardial infarction (MI).

Brigham researchers have demonstrated that in an older population with normal ejection fraction and sinus rhythm, age‐related left atrium reservoir dysfunction and stiffness—detectable on three-dimensional echocardiography (3DE)—were associated with higher odds of subclinical cerebral infarcts (SCIs) and stroke.

Over the past decade in cardiac surgery, health policy initiatives have been implemented to reduce sex and socioeconomic status disparities. To evaluate progress in the U.S., researchers at Brigham and Women’s Hospital recently conducted the largest nationally representative study to date.

Researchers at Brigham and Women’s Hospital have created Cardiac Rejection Assessment Neural Estimator (CRANE), a form of artificial intelligence for automated screening of endomyocardial biopsy results. They describe its performance and its potential to serve as an assistive diagnostic tool.

Researchers conducted the first rigorous, large-scale trial of long-term cocoa flavanol supplementation to prevent CVD and cancer. They found that cocoa extract supplementation led to a small but nonsignificant reduction in total cardiovascular events among older adults but significantly reduced CVD death by 27%.

Three cardiologists from the Division of Cardiovascular Medicine at the Brigham’s Heart & Vascular Center—Brian A. Bergmark, MD, Deepak L. Bhatt, MD, MPH, and Paul M. Ridker, MD, MPH—presented a total of four late-breaking clinical trials at the American College of Cardiology’s 71st Annual Scientific Session in April.

Researchers at Brigham and Women’s Hospital recently published a nationwide U.S. study of patients who received more than 90 days of oral anticoagulation after hospitalization for VTE. They found dispensing of apixaban, versus warfarin, was associated with a modestly lower hospitalization rate for recurrent VTE.